| European Case Law Identifier: | ECLI:EP:BA:2015:T222014.20151109 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 09 November 2015 | ||||||||
| Case number: | T 2220/14 | ||||||||
| Application number: | 02709544.7 | ||||||||
| IPC class: | C12N 15/00 | ||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | C | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | METHODS OF MODIFYING EUKARYOTIC CELLS | ||||||||
| Applicant name: | REGENERON PHARMACEUTICALS, INC. | ||||||||
| Opponent name: | Kymab Limited Merus B.V. Novo Nordisk A/S |
||||||||
| Board: | 3.3.08 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Postponement of the oral proceedings - (no) Admission of documents (139), (161), (169) to (172) and (175) - (no) Admission of documents (156), (158) and (168) - (yes) Reopening debate - (no) Confidentiality of documents (169) to (172) - (yes) Admission of main request filed at the oral proceedings - (yes) Requirements of the EPC fulfilled - (yes) |
||||||||
| Catchwords: |
Sufficiency of disclosure - see sections 55 to 72 |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t142220eu1.html
Date retrieved: 17 May 2021